JP Morgan Chase
IOVA icon

JP Morgan Chase’s Iovance Biotherapeutics IOVA Stock Holding History

JP Morgan Chase’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$470K – 7557
2024
Q3 		$470K Buy
50,000
+36,000
+257% +$341K ﹤0.01% 4936
2024
Q2 		$112K Buy
+14,000
New +$150K ﹤0.01% 5455
2021
Q4 		– Sell
-33,800
Closed -$834K – 6794
2021
Q3 		$834K Buy
+33,800
New +$796K ﹤0.01% 4437
2020
Q2 		– Sell
-60,500
Closed -$1.81M – 5526
2020
Q1 		$1.81M Buy
+60,500
New +$1.6M ﹤0.01% 3046

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase's IOVA Position: Q2 2026 in Review

JP Morgan Chase reduced its Iovance Biotherapeutics (IOVA) stake by 2.8% in Q2 2026, selling an estimated $262K and leaving 2,431,616 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

JP Morgan Chase first reported a position in IOVA in Q4 2015 and has held it in 41 quarters since. The position peaked at $65M in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • JP Morgan Chase held 2,431,616 shares of Iovance Biotherapeutics worth $10.2M as of Q2 2026.
  • JP Morgan Chase sold 69,008 Iovance Biotherapeutics shares in Q2 2026, an estimated $262K.
  • Iovance Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2775 holding.
  • JP Morgan Chase first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 41 quarters since.
  • JP Morgan Chase's Iovance Biotherapeutics position peaked at $65M in Q1 2024.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.